JANX News and Press, Janux Therapeutics Inc.

2024-07-01 11:13:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’ “ was previously published in May 2024. It has since been updated...

2024-06-26 08:32:44 ET Summary Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor...

2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...

2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-30 13:30:05 ET Wedbush analyst issues SECTOR PERFORM recommendation for JANX on May 30, 2024 11:01AM ET. The previous analyst recommendation was Sector Perform. JANX was trading at $50.07 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-05-30 13:30:05 ET Scotiabank analyst issues UNDERPERFORM recommendation for JANX on May 30, 2024 11:01AM ET. The previous analyst recommendation was Underperform. JANX was trading at $50.07 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2024-05-22 03:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-13 10:30:04 ET Wedbush analyst issues BUY recommendation for JANX on May 13, 2024 09:00AM ET. The previous analyst recommendation was Buy. JANX was trading at $49.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...

2024-05-07 17:59:35 ET More on Janux Therapeutics Janux Therapeutics: A Prime Target In Cancer Care's M&A Game Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux Therapeutics gain...

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term...